Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  NeuroOne Medical Technologies Corporation    NMTC


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

NeuroOne Medical Technologies : Announces Distribution Deal With Zimmer Biomet For Evo(TM) Cortical Electrode; Reduces Majority of Debt While Strengthening Balance Sheet

08/06/2020 | 08:54am EST

NeuroOne Medical Technologies Corporation (OTC: NMTC) finalized a development and distribution deal with Zimmer Biomet (NYSE: ZBH) to market its Evo(TM) Cortical Electrode (Evo), the Company's first FDA 510(k)-cleared product. The Evo Cortical Electrode is indicated for recording, monitoring and stimulating brain tissue for up to 30 days. The technology, utilizing sophisticated automated manufacturing processes, offers a thin-film lightweight design, high resolution capabilities, reduced immunological response-as demonstrated in pre-clinical studies-and the potential to be placed in a minimally invasive manner.

The terms of the deal announced in July provide Zimmer Biomet with exclusive global rights to distribute Evo, which is the result of collaborations between NeuroOne and the University of Wisconsin-Madison'sAlumni Research Foundation and the Mayo Foundation for Medical Education and Research.

Innovative Thin Film Evo Cortical Electrode

The deal with Zimmer Biomet is the second milestone for this innovative electrode, with the first coming from FDA 510(k) clearance, announced in December of 2019. Evo cortical electrodes are designed to be less invasive, improve the surgical experience and enhance mapping capabilities for people suffering from neurological disorders. In pre-clinical studies conducted by the Mayo Clinic, Evo demonstrated a reduction in the brain's immunological response, which should increase patient comfort and reduce signal artifacts associated with the brain electrode interface. This technology is expected to generate significant interest from neurologists and neurosurgeons managing patients with epilepsy and brain tumors.

Zimmer's involvement is expected to allow NeuroOne to focus its resources on the pursuit of additional applications of its technology and meeting initial launch order requests to initiate product commercialization.

In connection with the Zimmer distribution agreement, NeuroOne received an upfront payment, with the potential to receive back-end payments upon meeting certain milestones.

Second Product Seeking FDA 510(k) Clearance in Q4

The next product being developed by NeuroOne is a stereoelectroencephalography (sEEG) depth electrode, which NeuroOne anticipates submitting for FDA 510(k) clearance by the end of 2020. The sEEG depth electrode is an expansion of NeuroOne's thin film electrode platform that can access deep cortical structures (where its Evo cortical electrodes are only on the surface). Additionally, it can be implanted through tiny twist holes instead of a craniotomy. This design feature may lead to fewer complications, less post-operative pain, and shorter length of stay in the hospital. Like Evo, the new sEEG depth electrode will be indicated for recording, monitoring and stimulating brain tissue for up to 30 days.

Beyond the Evo electrode portfolio, NeuroOne's development pipeline includes an ablation electrode to record and remove targeted problematic brain tissue, a spinal cord stimulation electrode, and a deep brain stimulation electrode. Intended applications for these innovative devices include helping with epilepsy, Parkinson's Disease, dystonia, essential tremors, and chronic back pain due to failed surgeries.

These innovative thin film technologies leverage new research conducted by scientists using deep brain stimulation to treat psychological and mental disorders. To date, published clinical data has helped generate a spike in interest from respected biotech leaders and technology entrepreneurs.

To drive future development of its proven product pipeline, NeuroOne has created an advisory board of seven prominent artificial intelligence experts to assist in the technology's planning, development, and functional application. Artificial intelligence is expected to be an integral part of the company's next generation of electrode technology.

Balance Sheet Strengthened In July

In July, the Company retired approximately $3.3 million of debt, allowing the Company to transition towards planning commercialization, building its financial infrastructure, and focusing on additional product development.

To find out more visit https://get.ceo3in60.com/neuroone/


This communication was produced by PCG Digital Holdings, LLC, and affiliate of PCG Advisory Inc., (together "PCG"). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be 'Paid Advertising' for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the "Securities Act"). PCG may be compensated by respective clients for publicizing information relating to its client's securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures

Media Contact

Company Name: PCG Digital Holdings

Contact Person: Kenny Ellis

Email: info@ceo3in60.com

City: New York

State: New York

Country: United States

Website: https://pcgadvisory.com/

Source: www.abnewswire.com


(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ZIMMER BIOMET HOLDINGS -0.93% 149.68 Delayed Quote.0.00%
10/06NEUROONE MEDICAL TECHNOLOGIES CORP : Other Events, Financial Statements and Exhi..
09/03NEUROONE MEDICAL TECHNOLOGIES CORP : Unregistered Sale of Equity Securities (for..
08/25NEUROONE MEDICAL TECHNOLOGIES : Announces Zimmer Biomet Distribution Deal For It..
08/13NEUROONE MEDICAL TECHNOLOGIES : Management's Discussion and Analysis of Financia..
08/06NEUROONE MEDICAL TECHNOLOGIES : Announces Distribution Deal With Zimmer Biomet F..
08/03NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
07/28NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
07/22NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
07/02NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
06/04NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
More news
Financials (USD)
Sales 2019 - - -
Net income 2019 -6,78 M - -
Net cash 2019 0,26 M - -
P/E ratio 2019 -3,27x
Yield 2019 -
Capitalization 22,9 M 22,9 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 4
Free-Float 74,4%
Duration : Period :
NeuroOne Medical Technologies Corporation Technical Analysis Chart | NMTC | US64130M1009 | MarketScreener
Income Statement Evolution
David A. Rosa President, Chief Executive Officer & Director
Paul R. Buckman Chairman
Steven Mertens Chief Technology Officer
Jeffrey S. Mathiesen Independent Director
Edward S. Andrle Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS AG86.86%28 066